AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...

Read more →

Hopes $55k breast cancer drug Keytruda will get PBS listing

3 December 2022 - Women with triple negative breast cancer have been given new hope that immunotherapy drug Keytruda will ...

Read more →

Tezepelumab for the treatment of patients with severe asthma

2 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Agenda for the December 2022 PBAC intracycle meeting

2 December 2022 - The agenda for the December 2022 PBAC intracycle meeting is now available. ...

Read more →

Early breast cancer: indication of a minor additional clinical benefit of adjuvant therapy with olaparib

1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it ...

Read more →

‘Good news’ for Kiwi women as PHARMAC funds Utrogestan from today

1 December 2022 - The end of a decade long wait. ...

Read more →

Livtencity (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus infection

1 December 2022 - The conditions for the positive recommendation is supported by the findings of the Phase 3 SOLSTICE ...

Read more →

Lenvatinib mesylate in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma

30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Reimbursed access to Bylvay (odevixibat) approved in France for patients with PFIC 1 & 2

30 November 2022 - Albireo Pharma today announced that the Committee Economic Health Products has approved reimbursed access to Bylvay (odevixibat) ...

Read more →

Cemiplimab for the first-line treatment of patients wth advanced or metastatic PD-L1 positive non-small-cell lung cancer

1 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Schedule of Pharmaceutical Benefits - 1 December 2022

1 December 2022 - The December 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...

Read more →

New Zealand Pharmaceutical Schedule - 1 December 2022

1 December 2022 - The December 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

The Government may have taken money from the DHB hospital budget to increase PHARMAC's funding

30 November 2022 -  In this year’s budget, the Government said it has increased PHARMAC's funding by 43% over the ...

Read more →

Ripretinib for the treatment of patients with an advanced gastro-intestinal stromal tumour after three or more therapies

30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Mepolizumab for the treatment of patients with severe chronic rhinosinusitis with nasal polyps

29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →